17Dec/12

CTI announces preclinical study of Pixuvri, provides mechanism for lower … – pharmabiz.com

CTI announces preclinical study of Pixuvri, provides mechanism for lower …
pharmabiz.com
The EMA Committee for Medicinal Products for Human Use has accepted PIX306, CTI’s ongoing randomized controlled phase III clinical trial, which compares Pixuvri-rituximab to gemcitabine-rituximab in patients who have relapsed after one to three prior …

and more »